SMAD2 and lung cancer: Additionally, the activation of the Smad2/3 and Src/MAPK pathways, associated with GRP78 signaling in lung cancer, suggests that the knockdown of GRP78 inhibits the activation of Smad2/3 and Src, indicating a causal relationship between GRP78 and these pathways [30].